Kadhim AA, Jamal MY, Karim AK. Natalizumab Immunogenicity in Multiple Sclerosis: Evaluating Antibody Development and Clinical Outcomes in an Iraqi Cohort. Al-Rafidain J Med Sci [Internet]. 2025 Oct. 6 [cited 2026 Apr. 28];9(2):83-9. Available from: http://ajms.iq/index.php/ALRAFIDAIN/article/view/2352